Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem presented as a powder for solution for injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, nosocomial pneumonia, meningitis, severe urinary tract infections, skin and soft tissue infections, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections.

Complicated intra‑abdominal infections: effective bacterial eradication in patients with intra‑abdominal sepsis. Nosocomial pneumonia: rapid clearance of hospital‑acquired lung pathogens. Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. Severe urinary tract infections: eliminates resistant Gram‑negative uropathogens. Skin and soft tissue infections: resolves deep tissue infections caused by multidrug‑resistant bacteria. Sepsis: provides systemic coverage against a wide range of Gram‑negative and Gram‑positive organisms.

Meropenem may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Infusion site reactions: erythema or phlebitis at the injection site. - Elevated liver enzymes: transient increase in transaminases. - Rash: mild skin eruption.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Use meropenem with careful clinical assessment and monitoring.

Renal function assessment: adjust dose in patients with impaired renal function. Allergy assessment: avoid in patients with known hypersensitivity to carbapenems or other β‑lactam antibiotics. Seizure risk: monitor patients with central nervous system disorders or receiving high doses. Pregnancy and lactation: use only if the potential benefit justifies the potential risk; safety data are limited. Antimicrobial stewardship: restrict use to confirmed bacterial infections to limit resistance development. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Valproic acid: concomitant use may lower valproate levels and increase seizure risk. - Probenecid: may raise meropenem plasma concentrations, heightening toxicity. - Other carbapenems: concurrent use can lead to additive toxicity. - Nephrotoxic agents: avoid combined use with other kidney‑damaging drugs.

Moderate Interactions (Monitor Closely): - Aminoglycosides: monitor renal function when combined. - Loop diuretics: increased risk of nephrotoxicity; assess kidney parameters. - Anticoagulants (e.g., warfarin): monitor INR and adjust dose as needed.